The US Food and Drug Administration (FDA) has issued a new raft of warning letters to firms marketing glucagon‑like peptide‑1 (GLP‑1) receptor agonists and related compounds without required regulatory authorization.
On April 7, 2026, the FDA cited seven companies for distributing GLP‑1 products, dual GLP‑1/glucose‑dependent insulinotropic polypeptide (GIP) products,